David Resnick works with startup and established life sciences companies, as well as major U.S. research institutions, to develop comprehensive patent strategies to protect their intellectual property.
My practice is focused on strategic portfolio management, patent prosecution, transactional matters and associated client counseling. I manage the patent portfolios of some of the leading U.S. research institutions and domestic and international corporations. I also represent some of the world’s most recognized life sciences corporations before the U.S. Patent and Trademark Office. I have an extensive background in the life sciences space and have particular experience in the areas of microbiome related technologies, pharmacogenomics, disease biomarkers, proteomics, tissue engineering, gene therapy, regenerative medicine, drug delivery systems, stem cells, angiogenesis modulation, cancer vaccines, oncology, immune modulation, medical devices, and diagnostics.
I’ve written articles on patent prosecution practice, personalized medicine and technology issues for Nature Biotechnology, The Journal of Biolaw & Business, Personalized Medicine and other publications. I’m also a member of the editorial board of Pharmaceutical Patent Analyst.
I regularly assist clients in building and evaluating their intellectual property portfolios as well as in evaluating the intellectual property held by competitors. I regularly conduct freedom-to-operate analyses and prepare infringement and validity opinions involving complex and cutting-edge technologies.
I assist clients with patent prosecution in the areas of:
I work closely with my clients to identify and analyze acquisition targets and regularly conduct due diligence related to potential acquisitions.
In the aftermath of the Prometheus decision, and until such time as further judicial decisions provide greater clarity, I foresee that many life sciences companies will continue to struggle with respect to what qualifies as patent-eligible subject matter.
Microbiome Times | April 29, 2020
Boston Intellectual Property partners Mark FitzGerald and David Resnick co-authored this article analyzing a recent decision by the U.S. Patent Trial and Appeal Board to invalidate a University of Chicago U.S. microbiome patent. The authors note some positive aspects of that decision within the microbiome community, as it provides increased definition around what they can protect with patents.
Boston Business Journal | August 08, 2019
This story quotes Boston Intellectual Property partner David Resnick on best practices and challenges facing microbiome companies, which create novel disease-fighting treatments from naturally occurring substances, as they try to patent their innovations.
Webinar Recording | 04.22.20
Agricultural Biotech Patent Watch | 09.09.19
Originally recorded June 5, 2019 | 06.05.19
Patent Law Alert | 11.01.18
04.21.20 | Webinar
06.04.19 | Webinar
Syracuse University College of Law, J.D.
University of Rhode Island, M.S., Microbiology
University of Rhode Island, B.S., Microbiology
U.S. District Court, District of Massachusetts
U.S. Court of Appeals, Federal Circuit
U.S. Patent and Trademark Office
David is a member of the Association of University Technology Managers and the American Intellectual Property Law Association. David is also a member of the Personalized Medicine Coalition’s Public Policy Committee.